GL1X · GenesisL1 explorer

Research workbench

Structure of trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-139

Analyse Structure of trypanosoma cruzi dihydroorotate dehydrogenase in complex with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3W85
Type
protein
Length
626 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dihydroorotate dehydrogenase (fumarate)
EC
1.3.98.1
UniProt
Q4D3W2
Ligands
W85, FMN, NCO
Pockets
5 · best druggability 0.81

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BDihydroorotate dehydrogenase (fumarate) (EC 1.3.98.1)protein31340% helix, 21% strandQ4D3W2

Ligands and binding sites

  • W85 · 5-{2-[3-(methoxycarbonyl)phenyl]ethyl}-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid · ligand · 2 copies · chains A, B
  • FMN · Flavin mononucleotide · ligand · 2 copies · chains A, B
  • NCO · Cobalt hexammine(iii) · ligand · chains A
  • GOL · Glycerol · additive · 9 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15100.810.8862W85, GOL, FMN
26180.790.8567W85, GOL, FMN
31270.540.8223empty
41290.460.7720empty
51170.430.7619GOL

Interfaces

1 interface between chains.

  • A–B · 2451 Ų buried · 26 hydrogen bonds · protein-protein

Compared structures

  • 3W85 · Structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with TT2-3-139 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.